A 30-centre NHS neuromuscular network, coordinated through Muscular Dystrophy UK, is the institutional structure this workbook sizes before rozanolixizumab's NICE-commissioning scenario opens NHS access at an estimated 25 specialist centres.
UK generalised myasthenia gravis expertise sits inside a defined institutional network, not a broad national field. The NHS neuromuscular network comprises approximately 30 specialist centres, coordinated through the Muscular Dystrophy UK (MDUK) network, and the Myasthenia Gravis Association UK (MGA) maintains a patient registry of roughly 3,000 enrolled members. That coordination matters commercially: rozanolixizumab (Rystiggo, UCB) remains the FcRn-antagonist class's one live NICE bid, and a positive recommendation with an agreed PAS would open NHS commissioning at an estimated 25 specialist neuromuscular centres. Our KOL Universe gate (K1) starts by mapping exactly this kind of coordinated network before any single physician is scored.
That structure changes how AXLRx tiers influence in the UK. A centre inside the MDUK-coordinated network, with MGA registry linkage and NICE-submission relevance, carries different institutional weight than an isolated district neurology clinic, and our Tier Classification gate (K2) scores that distinction directly, alongside NICE-appraisal engagement history and IVIg/plasma-exchange crisis-management capability. No named individual physician enters the workbook; every entry is scored and verified at the institution level, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a centre with no real role in a future NICE resubmission, which is exactly what the K1-K6 gate structure is built to prevent.
The UK gMG institutional network: 30 NHS centres, one national registry, one NICE-commissioning scenario
| Institution/Network | Role | Scale |
|---|---|---|
| NHS Neuromuscular Network | Specialist centre network coordinated through Muscular Dystrophy UK (MDUK) | ~30 centres |
| Myasthenia Gravis Association UK (MGA) | National patient registry | ~3,000 enrolled members |
| Rozanolixizumab NICE-commissioning scenario | Specialist centres that would gain access on a positive NICE recommendation | ~25 centres |
Sources: Muscular Dystrophy UK (MDUK) network coordination; Myasthenia Gravis Association UK (MGA) 2023 survey; NICE TA1069 (efgartigimod, June 2025); Rystiggo (rozanolixizumab) NICE appraisal and UCB UK access commentary.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The 30-centre NHS neuromuscular network structure
- MDUK coordination and MGA patient-registry linkage as KOL-tiering signals
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- NICE-appraisal engagement history and crisis-management capability as weighting inputs
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and NICE-submission cross-checks
- why no placeholder institution ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the 30-centre NHS neuromuscular network and the rozanolixizumab NICE-commissioning scenario before the rest of the workbook is built out
- Every UK gMG institution sized and sourced from NHS network and NICE-submission data
- The 30-centre MDUK-coordinated network as the sizing anchor
- Universe boundaries: MDUK-network centres versus district neurology clinics
- Scientific-influence scoring across NICE-appraisal engagement and MGA registry linkage
- What separates a Tier 1 institution from a district-level referral clinic
- Influence inputs: NICE-submission engagement, crisis-management capability, MDUK network role
- Cross-checked against independent NICE and publication records
- Readiness scoring and channel recommendations per institution
- Sequencing implications for MSL deployment ahead of a rozanolixizumab NICE decision
- Territory-to-institution coverage map across the UK's devolved nations
- Where current MSL deployment has gaps
- Multi-market reach for institutions active beyond the UK, across EU5 neuromuscular networks
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live NHS network structure, NICE appraisal records, and institutional-affiliation data, not secondary summaries. No institution ships without a verification tag.
UK myasthenia gravis KOL sources: NICE TA1069 (efgartigimod, June 2025), NICE TA636 (eculizumab, terminated 2020), the Myasthenia Gravis Association UK 2023 survey, and the Muscular Dystrophy UK (MDUK) neuromuscular network directory.
- NHS neuromuscular network size (~30 centres) and MDUK coordination verified against the Muscular Dystrophy UK network directory
- MGA UK patient registry figure (~3,000 members) verified against the Myasthenia Gravis Association UK 2023 survey
- Rozanolixizumab NICE-commissioning scenario (~25 centres) verified against NICE TA1069 precedent and UCB UK access commentary
- Every institution entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK myasthenia gravis specialists ahead of a rozanolixizumab NICE decision. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.